Clinical investigation of tazobactam/piperacillin in urology

DOI

Bibliographic Information

Other Title
  • 泌尿器科領域におけるTazobactam/Piperacillinの臨床的検討

Abstract

We clinically investigated tazobactam/piperacillin (TAZ/PIPC), a newly developed injectable antibiotic, in 4 patients with acute uncomplicated pyelonephritis and in 11 patients with chronic complicated urinary tract infection.<BR>TAZ/PIPC was given at 1.25 or 2.5g b. i. d. for several days to 15 patients with urinary tract infection.<BR>Three patients with acute uncomplicated pyelonephritis and 7 patients with chronic complicated UTI were evaluated by the criteria of the UTI Commitee.<BR>In acute uncomplicated pyelonephritis, clinical efficacy was excellent in 1 and moderate in 2 out of 3 patients evaluated by the criteria of the UTI Committee. According to doctor's evaluation, clinical efficacy was excellent in 3 patients and good in 1.<BR>In chronic complicated UTI, clinical efficacy was moderate in 4 and poor in 3 out of 7 patients evaluated by the criteria of the UTI Commitee. According to doctor's evaluation, clinical efficacy was excellent in 1 patient, good in 9 and unknown in 1, the overall rate being 100%.<BR>Bacteriologically, all strains isolated from acute uncomplicated pyelonephritis were eradicated after TAZ/PIPC treatment.<BR>In chronic complicated UTI, 12 of 14 strains (85.7%) were eradicated after TAZ/PIPC treatment.<BR>Neither subjective adverse reactions nor abnormal laboratory findings related to the drug were observed.

Journal

  • CHEMOTHERAPY

    CHEMOTHERAPY 42 (Supplement2), 765-769, 1994

    Japanese Society of Chemotherapy

Keywords

Details 詳細情報について

Report a problem

Back to top